These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36865395)

  • 1. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States.
    Park H; Brown C; Wilson DL; Huang PL; Hernández-Con P; Horne P; Goodin A; Joseph A; Segal R; Cabrera R; Cook RL
    Prev Med Rep; 2023 Apr; 32():102138. PubMed ID: 36865395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
    Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
    Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs.
    Asher AK; Portillo CJ; Cooper BA; Dawson-Rose C; Vlahov D; Page KA
    Subst Use Misuse; 2016 Jul; 51(9):1218-23. PubMed ID: 27219274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
    Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
    Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
    Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
    Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
    Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
    Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    Ottman AA; Townsend ML; Hashem MG; Britt RB
    Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
    Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
    Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment.
    Lam D; Wong RJ; Tessier A; Zapata Y; Saldana E; Gish RG
    Gastroenterology Res; 2022 Dec; 15(6):343-352. PubMed ID: 36660471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.